DSNKY Stock UPDATES Daiichi Sankyo Co. Ltd. Ads (DSNKY) 17.4300
Post# of 273256
Posted On: 09/10/2014 6:58:39 PM
Daiichi Sankyo Co. Ltd. Ads (DSNKY) 17.4300 $DSNKY
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes
PR Newswire Europe - Tue Sep 02, 10:46AM CDT
- Results presented during ESC Congress 2014 Clinical Trial Update Hot Line session
Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe
PR Newswire Europe - Tue Sep 02, 5:07AM CDT
Daiichi Sankyo Company, Limited announced on September 1 details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe.
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
Why Portola Pharmaceuticals Inc. Stock Swooned
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 07, 3:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Portola Pharmaceuticals , a clinical-stage...
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/465jcl/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Amgen Inc. - Sanofi - Daiichi Sankyo Company, Limited - Novartis AG - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Dendreon Corporation - Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/46...ional_cell
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Business Wire - Mon Jun 23, 9:30AM CDT
Pieris AG announced that it has achieved a second milestone for its second program, and fifth milestone overall, in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment. The milestone is based on successful in vitro and in vivo studies validating a range of Anticalin(R) targeted protein drug candidates designed to bind a Daiichi Sankyo target. With this achievement, Pieris will transfer development responsibility of the program to Daiichi Sankyo, who will initiate further in vivo studies in non-human primates.
Pulmonary Embolism - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/263k7j/pulmonary) has announced the addition of the "Pulmonary Embolism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pulmonary Embolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Daiichi Sankyo Company, Limited - Bayer AG - D-Pharm Ltd. For more information visit http://www.researchandmarkets.com/research/263k7j/pulmonary
Sepsis - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rc2rw6/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Baxter International - Daiichi Sankyo Company - Novo Nordisk - Takeda Pharmaceutical Company - Chiesi Farmaceutici - Chong Kun Dang - Eisai - Huons - MetrioPharm - Opsona Therapeutics - Asahi Kasei - MSM Protein Technologies - VG Life Sciences - OncoImmune - Serum Institute of India - Endacea - ISU ABXIS - KAEL-GemVax - biosyn Arzneimittel - Cognosci - Navigen Pharmaceuticals - Lead Discovery Center - Immune Response BioPharma - Novadiscovery - XImmune - Adrenomed - ImmunNovative Developments - Diomune For more information visit http://www.researchandmarkets.com/research/rc...s_pipeline
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7cwmg2/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - MedImmune - Isis Pharmaceuticals - Gilead Sciences - Daiichi Sankyo Company - Merck & Co - CardioVascular BioTherapeutics - Bayer AG - AnGes MG - Pluristem Therapeutics - AngioDesign - ViroMed - Miltenyi Biotec - Multi Gene Vascular Systems - Lonestar Heart - Biscayne Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7c...ary_artery
Global Protein Therapeutics Market 2012-2016: Patent-Expiration of Top-Selling Drugs Could Pose a Challenge to the Growth
M2 - Mon Mar 31, 11:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5wp95/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/x5...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
PR Newswire Europe - Mon Mar 31, 6:01AM CDT
-- First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes
PR Newswire Europe - Tue Sep 02, 10:46AM CDT
- Results presented during ESC Congress 2014 Clinical Trial Update Hot Line session
Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe
PR Newswire Europe - Tue Sep 02, 5:07AM CDT
Daiichi Sankyo Company, Limited announced on September 1 details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe.
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
Why Portola Pharmaceuticals Inc. Stock Swooned
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 07, 3:29PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Portola Pharmaceuticals , a clinical-stage...
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/465jcl/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Amgen Inc. - Sanofi - Daiichi Sankyo Company, Limited - Novartis AG - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Dendreon Corporation - Cadila Pharmaceuticals Ltd. For more information visit http://www.researchandmarkets.com/research/46...ional_cell
Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global
Pieris Achieves Milestone Payment in Daiichi Sankyo Collaboration to Develop Anticalin(R) Therapeutics
Business Wire - Mon Jun 23, 9:30AM CDT
Pieris AG announced that it has achieved a second milestone for its second program, and fifth milestone overall, in its discovery and development collaboration with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment. The milestone is based on successful in vitro and in vivo studies validating a range of Anticalin(R) targeted protein drug candidates designed to bind a Daiichi Sankyo target. With this achievement, Pieris will transfer development responsibility of the program to Daiichi Sankyo, who will initiate further in vivo studies in non-human primates.
Pulmonary Embolism - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/263k7j/pulmonary) has announced the addition of the "Pulmonary Embolism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Embolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Embolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pulmonary Embolism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pulmonary Embolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Daiichi Sankyo Company, Limited - Bayer AG - D-Pharm Ltd. For more information visit http://www.researchandmarkets.com/research/263k7j/pulmonary
Sepsis - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rc2rw6/sepsis_pipeline) has announced the addition of the "Sepsis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Baxter International - Daiichi Sankyo Company - Novo Nordisk - Takeda Pharmaceutical Company - Chiesi Farmaceutici - Chong Kun Dang - Eisai - Huons - MetrioPharm - Opsona Therapeutics - Asahi Kasei - MSM Protein Technologies - VG Life Sciences - OncoImmune - Serum Institute of India - Endacea - ISU ABXIS - KAEL-GemVax - biosyn Arzneimittel - Cognosci - Navigen Pharmaceuticals - Lead Discovery Center - Immune Response BioPharma - Novadiscovery - XImmune - Adrenomed - ImmunNovative Developments - Diomune For more information visit http://www.researchandmarkets.com/research/rc...s_pipeline
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7cwmg2/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - MedImmune - Isis Pharmaceuticals - Gilead Sciences - Daiichi Sankyo Company - Merck & Co - CardioVascular BioTherapeutics - Bayer AG - AnGes MG - Pluristem Therapeutics - AngioDesign - ViroMed - Miltenyi Biotec - Multi Gene Vascular Systems - Lonestar Heart - Biscayne Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/7c...ary_artery
Global Protein Therapeutics Market 2012-2016: Patent-Expiration of Top-Selling Drugs Could Pose a Challenge to the Growth
M2 - Mon Mar 31, 11:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5wp95/global_protein) has announced the addition of the "Global Protein Therapeutics Market 2012-2016" report to their offering. The analysts forecast the Global Protein Therapeutics market to grow at a CAGR of 7.08 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of chronic diseases. The market has also been witnessing increasing outsourcing of drug development. The key vendors dominating this space include Roche Holding Ltd., Amgen Inc., Abbott Laboratories, J&J, and Novo Nordisk A/S. The other vendors mentioned in this report are AstraZeneca plc, Biogen Idec Inc., Eli Lilly and Co., Novartis International AG, Bristol Myers Squibb Co., Merck and Co. Inc., Pfizer Inc., Curis Inc., UCB S.A., Elan Corporations Plc, Human Genome Sciences Inc., Daiichi Sankyo Co. Ltd., and GlaxoSmithKline plc. Commenting on the report, an analyst from the Healthcare team said: The development and manufacture of drugs is a complex and time-consuming process, and also requires huge financial investments. As many vendors in the market are facing the problem of declining venture capital investments, they are increasingly following the strategy of outsourcing. Many vendors outsource different parts of the R&D process such as product characterization testing and toxicology testing to CROs. Likewise, a few vendors are increasingly outsourcing a part of their manufacturing process, or the entire manufacturing process to various organizations. Thus, the Global Protein Therapeutics market is currently witnessing the trend of increased outsourcing of drug development activities. For more information visit http://www.researchandmarkets.com/research/x5...al_protein About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
PR Newswire Europe - Mon Mar 31, 6:01AM CDT
-- First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion
(0)
(0)Scroll down for more posts ▼